Sarepta Therapeutics | SRPT - Ebitda


Sarepta Therapeutics reported $126.42M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Amgen USD 3.6B 147M Jun/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Incyte USD 581.52M 358.87M Jun/2025
Insmed USD -297.13M 71.11M Jun/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Moderna USD -208M 552M Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Tectonic Therapeutic USD -13.48M 5.73M Dec/2024
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025